# US 2003/0208041 A1 · Dermacentor variabilis gaba-gated chloride channels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0208041 A1
- Document ID: US20030208041A1
- Status: Published application
- Kind: A1
- Application number: 10/239,956
- Filed: 2002-09-25
- Published: 2003-11-06
- Earliest claimed: 2002-09-25
- Assignees: Merck & Co., Inc.
- Inventors: Yingcong Zheng; Doris F. Cully; Steve W. Ludmerer
- Web page: https://patentgrep.com/patent/US20030208041A1

## CPC

- C07K 14/43527: {from ticks}
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention features Dermacentor variabilis GABA-gated chloride channel polypeptides and nucleic acids, and uses of such polypeptides and nucleic acids. D. variabilis is a widely distributed tick associated with different diseases. A preferred use of the present invention is to obtain compounds for preventing or treating a tick infestation.

## Claims

### Claim 1

A purified polypeptide comprising a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, wherein said unique region is not present in SEQ. ID. NO. 7.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein said unique region comprises an amino acid sequence selected from the group consisting of:
5 QILNAFFTRG; (SEQ. ID. NO. 9) MTVGAEVAERIWVP; (SEQ. ID. NO. 10) RWSDGDTSVRIAK; (SEQ ID. NO. 11) TALLEYAAVGYLG; (SEQ. ID. NO. 12) RCAAASSNEPSSEPLLASPEVSIVKT; (SEQ. ID. NO. 13) QPREAPPTGFT; (SEQ. ID. NO. 14) MGRRGADQCCPGLQGSCQVC; (SEQ. ID. NO. 15) MEVRLKMVDPKGFSKSS; (SEQ. ID. NO. 16) HISDVLPDDVGDD; (SEQ. ID. NO. 17) HVSDVLPDDVGDD. (SEQ. ID. NO. 18)

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, and SEQ. ID. NO. 3.

### Claim 4 (depends on 3)

The polypeptide of claim 3, wherein said polypeptide consists of an amino acid sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, and SEQ. ID. NO. 3.

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide consists of an amino acid sequence having a sequence identity of at least 70% with SEQ. ID. NO. 1.

### Claim 6 (depends on 1)

A purified nucleic acid comprising a nucleotide sequence encoding for the polypeptide of claim 1.

### Claim 7 (depends on 5)

A purified nucleic acid comprising a nucleotide sequence encoding for the polypeptide of claim 5.

### Claim 8

A purified nucleic acid comprising a unique nucleotide sequence region of SEQ. ID. NO. 4, SEQ. ID. NO. 5, SEQ. ID. NO. 6 or the complement thereof, that is at least 18 contiguous nucleotides in length, wherein said unique region is not present in SEQ. ID. NO. 8 or the complement thereof.

### Claim 9 (depends on 8)

The purified nucleic acid of claim 8, wherein said unique region comprises a sequence selected from the group consisting of:
6 CAAACGCAACGTGGACAA; (SEQ. ID. NO. 20) GAGCGACTCTCGTTCCAG; (SEQ. ID. NO. 21) ATCGGCTCCGGAGGAGAG; (SEQ. ID. NO. 22) AAGGTCCTCGGTCACGTCCAAAAA; (SEQ. ID. NO. 23) CTCGGCAAGAGAATCACC; (SEQ. ID. NO. 24) GGTTCCTGTCAAGTTTGT; (SEQ. ID. NO. 25) GGTTCCTGTCGGGTTTGT; and (SEQ. ID. NO. 26) CCAACCGGATTTACCATG. (SEQ. ID. NO. 27)

### Claim 10 (depends on 8)

The purified nucleic acid of claim 8, wherein said nucleic acid comprises a sequence selected from the group consisting of the nucleotide sequence of SEQ. ID. NO. 4, SEQ. ID. NO. 5 and SEQ. ID. NO. 6.

### Claim 11 (depends on 10)

The purified nucleic acid of claim 10, wherein said nucleic acid consists of a sequence selected from the group consisting of the nucleotide sequence of SEQ. ID. NO. 4, SEQ. ID. NO. 5 and SEQ. ID. NO. 6.

### Claim 12

An expression vector comprising a recombinant nucleotide sequence encoding for a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, wherein said unique region is not present in SEQ. ID. NO. 7.

### Claim 13 (depends on 12)

The expression vector of claim 12, wherein said recombinant nucleotide sequence encodes for a polypeptide comprising a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.

### Claim 14 (depends on 12)

A recombinant cell comprising the expression vector of claim 12, wherein said recombinant nucleotide sequence is functionally coupled to a promoter recognized by said cell.

### Claim 15 (depends on 13)

A recombinant cell comprising the expression vector of claim 13, wherein said recombinant nucleotide sequence is functionally coupled to a promoter recognized by said cell.

### Claim 16 (depends on 12)

A recombinant cell made by a process comprising the step of introducing into said cell the expression vector of claim 12, wherein said recombinant nucleotide sequence is functionally coupled to a promoter recognized by said cell.

### Claim 17

A purified antibody preparation comprising an antibody that binds a polypeptide selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.

### Claim 18 (depends on 17)

The antibody of claim 17, wherein said polypeptide consists of the amino acid sequence of SEQ. ID. NO. 19 (LGKRITMRKTRCQQLAKLAEQ HRQR).

### Claim 19

A method of preparing a GABA-gated chloride polypeptide comprising the step of incubating a cell comprising a recombinant nucleotide sequence encoding for a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, wherein said unique region is not present in SEQ. ID. NO. 7, under conditions wherein said polypeptide is expressed.

### Claim 20

A method for assaying the binding of a compound to a D. variabilis GABA-gated chloride channel comprising the steps of:
a) expressing from a recombinant nucleic acid a polypeptide comprising a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, wherein said unique region is not present in SEQ. ID. NO. 7;
b) providing to said polypeptide a test preparation comprising one or more test compounds; and
c) measuring the ability of said test preparation to bind to said polypeptide.

### Claim 21 (depends on 20)

The method of claim 20, wherein said polypeptide consists of 9 contiguous amino acids up to the full-length sequence provided in SEQ. ID. NOs. 1, 2, or 3.

### Claim 22 (depends on 21)

The method of claim 21, wherein said steps (b) and (c) are performed in vitro.

### Claim 23 (depends on 21)

The method of claim 21, wherein said steps (a), (b) and (c) are performed using a whole cell.

### Claim 24 (depends on 21)

The method of claim 21, wherein said polypeptide is expressed from an expression vector.

### Claim 25 (depends on 24)

The method of claim 24, wherein said polypeptide consists of a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.

### Claim 26

A method of measuring GABA-gated chloride channel activity comprising the steps of:
a) contacting a recombinant cell with a compound, wherein said recombinant cell comprises a recombinant nucleotide sequence expressing a functional GABA-gated chloride channel that comprises a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, provided that said unique region is not present in SEQ. ID. NO. 7; and
b) measuring GABA-gated chloride channel activity.

### Claim 27 (depends on 26)

The method of claim 26, wherein said functional GABA-gated chloride channel comprises an amino sequence having a sequence identity of at least 70% with SEQ. ID. NO. 1.

### Claim 28 (depends on 26)

The method of claim 26, wherein said functional GABA-gated chloride channel comprises a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.

### Claim 29 (depends on 26)

The method of claim 26, wherein said functional GABA-gated chloride channel consists of a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2 and SEQ. ID. NO. 3.

### Claim 30

A method of decreasing or preventing a tick infestation comprising the steps of:
a) identifying a compound that modulates a D. variabilis GABA-gated chloride channel activity; and
b) using said compound to decrease or prevent a tick infestation.

### Claim 31 (depends on 30)

The method of claim 30, wherein said step (a) is performed by (i) contacting a recombinant cell with said compound, wherein said recombinant cell comprises a recombinant nucleotide sequence expressing a functional GABA-gated chloride channel that comprises a unique amino acid region of SEQ. ID. NO. 1, SEQ. ID. NO. 2, or SEQ. ID. NO. 3 that is at least 9 contiguous amino acids in length, provided that said unique region is not present in SEQ. ID. NO. 7 and (ii) measuring GABA-gated chloride channel activity.

### Claim 32 (depends on 31)

The method of claim 31, wherein said functional GABA-gated chloride channel comprises a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, and SEQ. ID. NO. 3.

### Claim 33 (depends on 32)

The method of claim 32, wherein said functional GABA-gated chloride channel consists of a sequence selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, and SEQ. ID. NO. 3.
